Core Viewpoint - Zhend Medical reported a net profit of 203 million yuan for Q1-Q3 2025, representing a decrease of 33.91%, with Q3 net profit at 75 million yuan, down 48.47% [1] Financial Performance - The revenue showed steady growth, while profits faced temporary pressure due to high base effects [1] - The company is entering the respiratory and anesthesia equipment sector through acquisitions, which opens new growth opportunities [1] Future Outlook - Zhend Medical aims to build a broader and deeper healthcare industry chain to support the development of high-quality medical services [1] - Based on the analysis of the Q3 report, long-tail product optimization, and expense input rhythm, the company is valued at 26.8 billion yuan, with a target price of approximately 101 yuan, maintaining a "strong buy" rating [1]

Investment Rating - The report maintains a "Strong Buy" rating for the company with a target price of 101 CNY, while the current price is 75.50 CNY [3]. Core Insights - The company's revenue for the first three quarters of 2025 reached 3.184 billion CNY, reflecting a growth of 1.88%, while the net profit attributable to shareholders was 203 million CNY, down 33.91% year-on-year [2][3]. - The decline in net profit is attributed to a high base effect from the previous year, where a significant asset disposal contributed approximately 93 million CNY to the net profit [3]. - The company has entered the respiratory and anesthesia equipment sector through the acquisition of Ningbo Shengyu Rui Medical Equipment Co., which is expected to enhance its product offerings and market penetration [3]. Financial Performance Summary - For the first three quarters of 2025, the company reported: - Total revenue of 3.184 billion CNY (+1.88%) - Net profit of 203 million CNY (-33.91%) - Non-recurring net profit of 183 million CNY (-18.79%) [2]. - In Q3 2025, the company achieved: - Revenue of 1.084 billion CNY (+0.10%) - Net profit of 75 million CNY (-48.47%) - Non-recurring net profit of 65 million CNY (+2.00%) [2]. - Financial projections for 2024A to 2027E indicate a gradual increase in total revenue from 4.264 billion CNY in 2024 to 5.332 billion CNY in 2027, with corresponding net profits expected to rise from 385 million CNY to 395 million CNY [2][3]. Valuation Metrics - The projected P/E ratios for 2025E, 2026E, and 2027E are 65, 59, and 52 respectively, while the P/B ratios are expected to be 3.6, 3.4, and 3.3 [2][3]. - The report estimates the company's overall valuation at 26.8 billion CNY based on DCF modeling [3].

Core Viewpoint - Zhendemedical has shown significant stock performance with a year-to-date increase of 269.26%, indicating strong market interest and potential growth in the medical supplies sector [1][2]. Financial Performance - For the period from January to September 2025, Zhendemedical reported a revenue of 3.184 billion yuan, reflecting a year-on-year growth of 1.88%. However, the net profit attributable to shareholders decreased by 33.91% to 203 million yuan [2]. - The company has distributed a total of 1.46 billion yuan in dividends since its A-share listing, with 706 million yuan distributed over the past three years [3]. Stock Market Activity - As of November 25, Zhendemedical's stock price reached 78.80 yuan per share, with a market capitalization of 20.996 billion yuan. The stock experienced a net inflow of 26.7841 million yuan from major funds [1]. - The stock has appeared on the "龙虎榜" (a list of stocks with significant trading activity) four times this year, with the latest appearance on November 17, where it recorded a net buy of 329,100 yuan [1]. Shareholder Information - As of September 30, 2025, Zhendemedical had 23,600 shareholders, an increase of 4.06% from the previous period. The average number of circulating shares per shareholder decreased by 3.90% to 11,308 shares [2][3]. - Hong Kong Central Clearing Limited is the fourth-largest circulating shareholder, holding 3.9382 million shares, which is an increase of 190,000 shares from the previous period [3].

Core Points - Zhendemedical (603301) closed at 77.25 yuan on November 24, 2025, with a market capitalization of 20.583 billion yuan, reflecting a 2.33% increase from the previous trading day [1] - The stock opened at 75.27 yuan, reached a high of 77.29 yuan, and a low of 74.39 yuan, with a trading volume of 4.91 billion yuan and a turnover rate of 2.42% [1] Company Actions - Zhendemedical announced the implementation of a partial share repurchase and cancellation related to its first employee stock ownership plan, due to unmet performance targets for the third unlocking period [1] - The company decided to repurchase and cancel 615,667 shares at a price of 25.16 yuan per share, funded by its own resources [1] - This repurchase and cancellation were completed on November 27, 2025, reducing the total share capital from 266,451,202 shares to 265,835,535 shares [1] - The action does not affect the company's financial status, operating results, or listing status, and does not harm the interests of the company and its shareholders [1]

Group 1 - The core point of the article is that Zhend Medical announced the repurchase and cancellation of 615,667 shares due to the failure to meet performance assessment indicators for the third unlocking period of the first employee stock ownership plan [2] - The cancellation date for the repurchased shares is set for November 27, 2025 [2]

证券代码：603301 证券简称：振德医疗 公告编号：2025-042 本次回购注销股份的有关情况： | 回购股份数量（股） | 注销股份数量（股） | | 注销日期 | | | | --- | --- | --- | --- | --- | --- | | 615,667 | 615,667 | 2025 | 年 11 | 月 | 27 日 | 一、本次回购注销的决策与信息披露 1、公司分别于 2025 年 7 月 23 日、8 月 11 日召开第三届董事会 第二十二次会议、第三届监事会第十九次会议及 2025 年第一次临时 股东大会审议通过了《关于<公司第一期员工持股计划（草案修订稿） 及其摘要>的议案》、《关于<公司第一期员工持股计划管理办法（修订 稿）>的议案》、《关于回购公司第一期员工持股计划未解锁股份的议 案》、《关于变更部分回购股份用途并注销的议案》及《关于取消监事 会、变更公司注册资本、增加经营范围暨修订<公司章程>并办理工商 变更登记的议案》，同意将本员工持股计划未能解锁的 615,667 股公 司股份予以回购注销。具体内容详见公司于 2025 年 7 月 24 日在上海 证券交易所网站（w ...

Core Points - Zhendemedical (603301) closed at 75.49 yuan on November 21, 2025, down 14.79% from last week's 88.59 yuan [1] - The company's current market capitalization is 20.114 billion yuan, ranking 11th out of 126 in the medical device sector and 909th out of 5167 in the A-share market [1] Trading Information Summary - Zhendemedical was listed on the "Dragon and Tiger List" due to a price drop deviation of 7% on November 17, 2025, marking the first time in the last five trading days [1][3] Company Announcement Summary - Zhendemedical plans to engage in hedging activities related to polyethylene, polypropylene, and rubber to mitigate the impact of raw material price fluctuations on its operations. The maximum margin for this trading is set at 30 million yuan, with a maximum contract value of 200 million yuan, funded by the company's own resources. The trading period will last for 12 months from the date of board approval, which has already been granted without the need for shareholder meeting approval [1]

Core Viewpoint - Zhendemedical (603301) is initiating hedging activities to mitigate the impact of raw material price fluctuations on its operations, with a focus on polyethylene, polypropylene, and rubber [1][2]. Group 1: Stock Performance - As of November 20, 2025, Zhendemedical's stock closed at 77.0 yuan, down 1.8% from the previous trading day, with a total market capitalization of 20.517 billion yuan [1]. - The stock opened at 78.8 yuan, reached a high of 79.94 yuan, and a low of 76.76 yuan, with a trading volume of 3.78 billion yuan and a turnover rate of 1.83% [1]. Group 2: Hedging Business Announcement - The company plans to engage in financial derivative hedging related to raw materials to reduce the impact of price volatility on its operations [1]. - The maximum trading margin is set at 30 million yuan, with a maximum contract value not exceeding 200 million yuan, funded by the company's own resources [1]. - The trading period will last for 12 months from the date of approval by the board of directors, and this initiative has been approved by the fourth meeting of the company's fourth board of directors without requiring shareholder meeting approval [1]. Group 3: Risk Management - The company acknowledges potential risks associated with market, policy, performance, technology, and operational aspects, and has established corresponding risk control measures [1].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 交易主要情况 证券代码：603301 证券简称：振德医疗 公告编号：2025-041 振德医疗用品股份有限公司 关于开展套期保值业务的公告 （二）交易金额 公司开展套期保值业务在授权期内任一时点保证金额度不超过人民币 3,000 万元，该额度可循环使用；任一时点持有的最高合约价值不超过人民币 20,000 万元。 | 交易目的 | □获取投资收益 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 套期保值（合约类别：商品；□外汇；□其他：________） □其他：________ | | | | | | | | | | | 交易品种 | 聚乙烯、聚丙烯及橡胶等原材料相关的金融衍生品 | | | | | | | | | | | 交易金额 | 预计动用的交易保证金和权利金上限（单位：万元） | | | | | | | | | 3, ...

Group 1 - The core point of the article highlights the recent decline in the stock price of Zhendemedical, which fell by 5.16% to 76.02 yuan per share, with a trading volume of 398 million yuan and a turnover rate of 1.91%, resulting in a total market capitalization of 20.256 billion yuan [1] - Zhendemedical, established on August 18, 1994, and listed on April 12, 2018, specializes in the production, research, and sales of medical dressings. The main revenue composition includes: surgical infection control 43.04%, basic care 20.46%, ostomy and modern wound care 18.59%, pressure treatment and fixation 10.75%, infection control protection 6.58%, and others 0.58% [1] Group 2 - From the perspective of major fund holdings, data shows that one fund under Jiashi Fund has a significant position in Zhendemedical. Jiashi New Tanghui Regular Mixed A (005088) held 10,200 shares in the third quarter, accounting for 1.03% of the fund's net value, making it the third-largest holding. The estimated floating loss today is approximately 42,200 yuan [2] - Jiashi New Tanghui Regular Mixed A (005088) was established on September 28, 2017, with a latest scale of 45.2371 million yuan. Year-to-date return is 14.94%, ranking 5064 out of 8140 in its category; the one-year return is 10.12%, ranking 5745 out of 8057; and since inception, it has incurred a loss of 5.7% [2]